Esperion Therapeutics (ESPR) said Monday it has submitted New Drug Submissions to Health Canada for Nexletol and Nexlizet, oral non-statin medications designed to lower LDL cholesterol and potentially reduce cardiovascular risks in patients unable to tolerate statins.
The company said the medications are intended for adults with established cardiovascular disease or those at high risk of a cardiovascular event.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。